PE ratio relative to earnings growth — is the valuation justified?
0.23
PEG Ratio
Growth rate exceeds 100% — PEG may be misleadingly low; treat with caution
0.23
Growth Rate Source
Limited Data Quality3-Year EPS CAGR
Current Price
$99.30
TTM EPS
$4.14
P/E Ratio
23.99
Growth Rate
103.6%
3-Year EPS CAGR
Sector
Healthcare
Drug Manufacturers - Specialty & Generic
Calculated
8/18/2026
11:52:16 AM
Peer Comparison
Sample Size
2 peers
Industry Median PEG
0.61
25th Percentile
0.08
75th Percentile
1.13
LNTH PEG (0.23) vs Industry Median (0.61): 62% discount
Symbol
Company
PEG
P/E
Growth
vs LNTH
AMPH
Amphastar Pharmaceuticals, Inc.
0.08
11.6
146.0%
-66%
MEDP
Medpace Holdings, Inc.
1.13
35.0
30.9%
+389%
How to Interpret PEG Ratio
PEG < 1.0 — Potentially Undervalued. The stock may be priced below its earnings growth rate, suggesting a potential buying opportunity.
PEG 1.0–2.0 — Fairly Valued. The stock price is roughly in line with its earnings growth. A PEG of 1.0 is often considered "fair value."
PEG > 2.0 — Potentially Overvalued. The stock may be priced above what its earnings growth justifies.
Limitations:PEG ratios are less reliable for financial firms (earnings driven by interest margins), companies with negative/zero earnings growth, and hypergrowth companies (>100% growth) where the ratio may appear misleadingly low. Always use PEG alongside other valuation metrics.
